News InflaRx N.V.

Equities

IFRX

NL0012661870

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.63 ^USD	+12.41%		+38.14%	0.00%

May. 08	InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Transcript : InflaRx N.V. - Special Call

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update	May. 08	AQ
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024	Apr. 30	AQ
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed	Apr. 26	PU
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K	Apr. 25	PU
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event	Apr. 24	AQ
Transcript : InflaRx N.V. - Special Call	Mar. 21
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
InflaRx N : News Conference Call March 2024	Mar. 21	PU
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans	Mar. 21	AQ
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024	Mar. 19	AQ
InflaRx Appoints Jan Medina as Head of Investor Relations	Feb. 22	AQ
InflaRx N.V. Appoints Jan Medina as Head of Investor Relations	Feb. 22	CI
HC Wainwright Adjusts Price Target on InflaRx to $8 From $9, Keeps Buy Rating	Jan. 25	MT
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients	Jan. 25	GL
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904	Jan. 04	CI
Transcript : InflaRx N.V. - Special Call	Jan. 04
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904	Jan. 04	AQ
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	Nov. 06	AQ
InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	Nov. 06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News InflaRx N.V.

Equities

IFRX

NL0012661870

Summary

Filters